KMT2C and Kleefstra syndrome: In addition, pathogenic de novo variants in MBD5 and in other epigenetic regulators (SMARCB1, NR1I3, KMT2C) were reported in individuals with a clinical diagnosis of Kleefstra syndrome (KS; OMIM #610253) [115,116].